FDA limits J&J COVID-19 vaccine authorization due to blood clot risk

Published



The Food and Drug Administration narrowed its use authorization for Johnson & Johnson’s single-dose COVID-19 vaccine due to risks of severe blood clotting, a move that comes months after an initial warning from health officials.

The vaccine, produced by J&J subsidiary Janssen, should only be administered when an mRNA vaccine from Pfizer-BioNTech or Moderna is unavailable due to the risk of severe blood clotting known as thrombosis with thrombocytopenia syndrome, or TTS, the FDA announced Thursday.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.